The DDD pipeline is positioned at the top of the board to maintain visibility of the primary learning outcome throughout gameplay. Sequential stages reinforce that medicines must pass through multiple defined phases prior to approval, while the extended layout across the width of the board reflects the prolonged timescale of development. Progression criteria vary across stages, modelling how scientific, financial, and societal priorities shift throughout DDD.
1. Drug Development Pipeline
(click image to enlarge)
Introducing a new candidate requires players to collectively contribute three matching dice, reinforcing the collaborative nature of DDD through a shared objective.
The staff allocation pools form the central decision-making system. Players assign dice, representing ‘staff members on their team’, to research, fundraising, outreach, or developing new candidates. This encourages discussion, negotiation, and coordinated strategy.
2. Staff Allocation Pools
Three resources underpin progression: funds, data, and impact. Together, these resources require players to balance scientific, financial, and societal priorities, supporting understanding of the trade-offs involved in DDD.
3. Resource Management
Funds represent the financial investment required to bring a medicine to market. The tracker increases to £2 billion, reflecting published estimates of real-world development costs.
Data represents the scientific evidence needed to progress between stages. Players must accumulate data over multiple rounds, reflecting how DDD relies on evidence generated gradually through repeated testing.
Impact represents public trust, ethical considerations, and treatment value. This highlights that successful development depends not only on scientific and financial progress, but also on maintaining credibility, social responsibility, and patient benefit.
Game Board
McKenna
Created on March 30, 2026
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Practical Interactive Image
View
Akihabara Square Interactive Image
View
Akihabara Interactive Image
View
Essential Interactive Image
View
Interactive Team Image
View
Image with Audio
View
Image with interactive hotspots
Explore all templates
Transcript
The DDD pipeline is positioned at the top of the board to maintain visibility of the primary learning outcome throughout gameplay. Sequential stages reinforce that medicines must pass through multiple defined phases prior to approval, while the extended layout across the width of the board reflects the prolonged timescale of development. Progression criteria vary across stages, modelling how scientific, financial, and societal priorities shift throughout DDD.
1. Drug Development Pipeline
(click image to enlarge)
Introducing a new candidate requires players to collectively contribute three matching dice, reinforcing the collaborative nature of DDD through a shared objective.
The staff allocation pools form the central decision-making system. Players assign dice, representing ‘staff members on their team’, to research, fundraising, outreach, or developing new candidates. This encourages discussion, negotiation, and coordinated strategy.
2. Staff Allocation Pools
Three resources underpin progression: funds, data, and impact. Together, these resources require players to balance scientific, financial, and societal priorities, supporting understanding of the trade-offs involved in DDD.
3. Resource Management
Funds represent the financial investment required to bring a medicine to market. The tracker increases to £2 billion, reflecting published estimates of real-world development costs.
Data represents the scientific evidence needed to progress between stages. Players must accumulate data over multiple rounds, reflecting how DDD relies on evidence generated gradually through repeated testing.
Impact represents public trust, ethical considerations, and treatment value. This highlights that successful development depends not only on scientific and financial progress, but also on maintaining credibility, social responsibility, and patient benefit.